Results 131 to 140 of about 615,106 (215)

Differentiating high‐ and low‐grade serous ovarian carcinoma using radiomics: a pilot study

Ultrasound in Obstetrics &Gynecology, EarlyView.
ABSTRACT Objective To identify ultrasound‐based radiomics features capable of distinguishing between high‐grade serous ovarian carcinomas (HGSC) and invasive low‐grade serous ovarian carcinomas (LGSC), and to develop machine‐learning models that include radiomics features to discriminate between the two.
F. Ciccarone, G. Zinicola, E. H. Tran, G. Baldassari, E. Boccia, C. Nero, F. Moro, T. Pasciuto, G. Scambia, G. Ferrandina, A. Fagotti, A. C. Testa, D. Lorusso, Collaborators, F. Borella, F. Buonomo, R. Fruscio, F. Pozzati   +17 more
wiley   +1 more source

Poly(ADP-ribosyl)ation in mammalian ageing

, 2007
Poly(ADP-ribose) polymerases (PARPs) catalyze the post-translational modification of proteins with poly(ADP-ribose). Two PARP isoforms, PARP-1 and PARP-2, display catalytic activity by contact with DNA-strand breaks and are involved in DNA baseexcision ...
Beneke, Sascha, Bürkle, Alexander
core   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source

The discovery of small molecule inhibitors of poly(ADP-ribose) mediated cell death [PDF]

, 2011
The emergence of resistance to cancer treatments through methods that generate cell death by inducing DNA damage, such as chemotherapeutics and radiation therapy, is a major obstacle to overcoming the disease.
Finch, Kristin E.
core  

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

BJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics, Dániel Bacsó, Nadeen Samaien, Isabel Pinto Amorim das Virgens, Mahmoud Obeidat, Gergely Bánfi, Boris Hadaschik, Péter Hegyi, Péter Nyirády, Tibor Szarvas   +9 more
wiley   +1 more source

Modulation of chromatin superstructure induced by poly(ADP-ribose) synthesis and degradation

, 1986
It has been demonstrated recently by Poirier et al. (Poirier, G. G., de Murcia, G., Jongstra-Bilen, J., Niedergang, C., and Mandel, P. (1982) Proc. Natl. Acad. Sci. U.S.A.
Lamarre, D, Poirier, G G, Gaudreau, A, Pouyet, J, Daune, M, Murcia, G,, Huletsky, A   +6 more
core  

ART2, a T cell surface mono-ADP-ribosyltransferase, generates extracellular poly(ADP-ribose)

, 2008
Medical student Alan Morrison participated in this study as part of the Senior Scholars research program.NAD functions in multiple aspects of cellular metabolism and signaling through enzymes that covalently transfer ADP-ribose from NAD to acceptor ...
Morrison, Alan R., Moss, Joel, Merithew, Eric Lee, Bortell, Rita, Evans, James E., Farrell, Caitlin, Mordes, John P., Stevens, Linda A., Lambright, David G., Rossini, Aldo A., Greiner, Dale L.   +10 more
core   +1 more source

Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

Brain Pathology, EarlyView.
DNA methylation profiling identifies GPAP as a distinct circumscribed glioma with a characteristic expansive, multicystic radiological appearance, pleomorphic and pseudopapillary histology, a recognizable CNV profile, druggable molecular alterations, and recurrent cancer predisposition syndromes.
Alberto Picca, Valeria Barresi, Aude Trinquet, Luca Bertero, Lucia Nichelli, Guillaume Chotard, Michèle Bernier, Thomas Gareau, Salah Eddine Oussama Kacimi, Jaydutt Bhalshankar, Mathilde Filser, Julien Masliah‐Planchon, Marta Iollo, Henri Malaize, Bertrand Mathon, Luc Bauchet, Kifah Khouri, Besma Barka, Hélène Madry, Sabrina Rossi, Evelina Miele, Giuseppe Kenneth Ricciardi, Catherine Carpentier, Irina Coin, Marc Sanson, Mehdi Touat, Caroline Dehais, Alessia Pellerino, Roberta Rudà, Paola Cassoni, Valérie Rigau, Emmanuelle Uro‐Coste, Karima Mokhtari, Ahmed Idbaih, Patrick R. Benusiglio, Franck Bielle   +35 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source